JP2019517507A - 特定の癌の治療のためのラムシルマブとペンブロリズマブとの組み合わせ - Google Patents

特定の癌の治療のためのラムシルマブとペンブロリズマブとの組み合わせ Download PDF

Info

Publication number
JP2019517507A
JP2019517507A JP2018563067A JP2018563067A JP2019517507A JP 2019517507 A JP2019517507 A JP 2019517507A JP 2018563067 A JP2018563067 A JP 2018563067A JP 2018563067 A JP2018563067 A JP 2018563067A JP 2019517507 A JP2019517507 A JP 2019517507A
Authority
JP
Japan
Prior art keywords
antibody
administered
dose
vegfr
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018563067A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019517507A5 (enExample
Inventor
ブライアン ゲイナー，リチャード
ブライアン ゲイナー，リチャード
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of JP2019517507A publication Critical patent/JP2019517507A/ja
Publication of JP2019517507A5 publication Critical patent/JP2019517507A5/ja
Priority to JP2021059858A priority Critical patent/JP7372955B2/ja
Priority to JP2022151872A priority patent/JP2022184998A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018563067A 2016-06-03 2017-05-26 特定の癌の治療のためのラムシルマブとペンブロリズマブとの組み合わせ Withdrawn JP2019517507A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021059858A JP7372955B2 (ja) 2016-06-03 2021-03-31 特定の癌の治療のためのラムシルマブとペンブロリズマブとの組み合わせ
JP2022151872A JP2022184998A (ja) 2016-06-03 2022-09-22 特定の癌の治療のためのラムシルマブとペンブロリズマブとの組み合わせ

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201662345322P 2016-06-03 2016-06-03
US62/345,322 2016-06-03
US201662377852P 2016-08-22 2016-08-22
US62/377,852 2016-08-22
US201662398663P 2016-09-23 2016-09-23
US62/398,663 2016-09-23
US201662434466P 2016-12-15 2016-12-15
US62/434,466 2016-12-15
US201762460404P 2017-02-17 2017-02-17
US62/460,404 2017-02-17
US201762469670P 2017-03-10 2017-03-10
US62/469,670 2017-03-10
PCT/US2017/034732 WO2017210119A1 (en) 2016-06-03 2017-05-26 Combination of ramucirumab and pembrolizumab for the treatment of certain cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021059858A Division JP7372955B2 (ja) 2016-06-03 2021-03-31 特定の癌の治療のためのラムシルマブとペンブロリズマブとの組み合わせ

Publications (2)

Publication Number Publication Date
JP2019517507A true JP2019517507A (ja) 2019-06-24
JP2019517507A5 JP2019517507A5 (enExample) 2019-07-25

Family

ID=59067893

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018563067A Withdrawn JP2019517507A (ja) 2016-06-03 2017-05-26 特定の癌の治療のためのラムシルマブとペンブロリズマブとの組み合わせ
JP2021059858A Active JP7372955B2 (ja) 2016-06-03 2021-03-31 特定の癌の治療のためのラムシルマブとペンブロリズマブとの組み合わせ
JP2022151872A Withdrawn JP2022184998A (ja) 2016-06-03 2022-09-22 特定の癌の治療のためのラムシルマブとペンブロリズマブとの組み合わせ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021059858A Active JP7372955B2 (ja) 2016-06-03 2021-03-31 特定の癌の治療のためのラムシルマブとペンブロリズマブとの組み合わせ
JP2022151872A Withdrawn JP2022184998A (ja) 2016-06-03 2022-09-22 特定の癌の治療のためのラムシルマブとペンブロリズマブとの組み合わせ

Country Status (4)

Country Link
US (1) US20190183972A1 (enExample)
EP (1) EP3463456A1 (enExample)
JP (3) JP2019517507A (enExample)
WO (1) WO2017210119A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
KR102843438B1 (ko) 2017-06-02 2025-08-06 바이엘 헬쓰케어 엘엘씨 암을 치료하기 위한 레고라페닙 및 pd-1/pd-l1(2) 억제제의 조합
WO2020093993A1 (zh) * 2018-11-06 2020-05-14 江苏恒瑞医药股份有限公司 一种抗pd-1抗体和法米替尼联合在制备治疗肿瘤的药物中的用途
US20220177561A1 (en) 2018-12-11 2022-06-09 Sanford Burnham Prebys Medical Discovery Institute Models and Methods Useful for the Treatment of Serrated Colorectal Cancer
WO2022049526A1 (en) * 2020-09-02 2022-03-10 Pharmabcine Inc. Combination therapy of a pd-1 antagonist and an antagonist for vegfr-2 for treating patients with cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016519121A (ja) * 2014-03-04 2016-06-30 イーライ リリー アンド カンパニー 癌のための併用療法
JP2017515859A (ja) * 2014-05-15 2017-06-15 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体と他の抗癌剤の組み合わせを使用する肺癌の処置
JP2017535528A (ja) * 2014-10-03 2017-11-30 ノバルティス アーゲー 組み合わせ治療

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2478169C (en) 2002-03-04 2013-04-16 Imclone Systems Incorporated Human antibodies specific to kdr and uses thereof
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016519121A (ja) * 2014-03-04 2016-06-30 イーライ リリー アンド カンパニー 癌のための併用療法
JP2017515859A (ja) * 2014-05-15 2017-06-15 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体と他の抗癌剤の組み合わせを使用する肺癌の処置
JP2017535528A (ja) * 2014-10-03 2017-11-30 ノバルティス アーゲー 組み合わせ治療

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BANG, YJ.: "Safety and efficacy of pembrolizumab (MK-3475) in patients with advanced biliary tract cancer: Inter", WWW.MDLINX.COM, 2015.09, [RETRIEVED ON 2019.12.16], RETRIEVED FROM THE INTERNET: <URL: HTTPS://WWW.M, JPN6019050360, ISSN: 0004394939 *
J. CLINICAL ONCOLOGY, 2016.05.20, VOL.34, NO.15, SUPPL_ABSTRACT NO.3056, JPN6019050359, ISSN: 0004394938 *

Also Published As

Publication number Publication date
JP2022184998A (ja) 2022-12-13
JP2021113195A (ja) 2021-08-05
EP3463456A1 (en) 2019-04-10
US20190183972A1 (en) 2019-06-20
WO2017210119A1 (en) 2017-12-07
JP7372955B2 (ja) 2023-11-01

Similar Documents

Publication Publication Date Title
JP7122357B2 (ja) がんの治療のための方法、組成物、及びキット
TWI780994B (zh) 用於治療非小細胞肺癌之抗b7-h1及抗ctla-4抗體
JP7372955B2 (ja) 特定の癌の治療のためのラムシルマブとペンブロリズマブとの組み合わせ
RU2695332C2 (ru) Лечение рака легкого с помощью комбинации антитела против pd-1 и другого противоракового средства
WO2013138371A1 (en) Methods for treating pancreatic cancer using combination therapies comprising an anti-erbb3 antibody
JP2023502585A (ja) 癌の治療のための、ＰＤ－１、ＴＧＦβ、及びＴＩＧＩＴの組み合わせ阻害
CN119746058A (zh) 治疗小细胞肺癌的联用药物组合物
JP2020506945A (ja) がんの治療のための方法、組成物及びキット
JP2025060639A (ja) Ｐｄ－１／ｐｄ－ｌ１シグナル伝達阻害剤に不応答性のがんの処置方法および医薬
US20240327519A1 (en) Methods and compositions for treating cancer
CN121079315A (zh) 用于组合疗法的方法和组合物
CN117202934A (zh) 抗pd-1抗体联合一线化疗治疗晚期非小细胞肺癌的用途
KR20230069957A (ko) 암을 갖는 환자의 치료를 위한 pd-1 길항제 및 lag3 길항제 및 렌바티닙 또는 이의 약학적으로 허용가능한 염의 병용 요법
CN116406288A (zh) 使用PD-1拮抗剂、HIF-2α抑制剂、以及乐伐替尼或其药学上可接受的盐的组合，用于治疗癌症或冯-希佩尔-林道病的方法
JP7064544B2 (ja) 癌の治療のための抗ｖｅｇｆｒ－２抗体と抗ｐｄ－ｌ１抗体との組み合わせ
CN118176021A (zh) 抗ctla-4抗体给药方案
CN118871128A (zh) 抗tim-3抗体与抗pd-l1抗体的药物组合
JP2024511977A (ja) 抗ｉｌｔ３抗体によるがんの治療方法
TW202508632A (zh) 使用抗ｐｄ－１及化學療法治療肺癌
CN120346313A (zh) 治疗肿瘤的药物组合

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200323

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200619

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210331

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210331

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210528

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210601

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20210604